The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis
Open accessAbstract
Background Elevated lipoprotein(a) (Lp[a]) is associated with aortic stenosis (AS). Oxidized phospholipids (OxPL) are key mediators of calcification in valvular cells and are carried by Lp(a).Objectives This study sought to determine whether Lp(a) and OxPL are associated with hemodynamic progression of AS and AS-related events.Methods OxPL on apolipoprotein B-100 (OxPL-apoB), which reflects the biological activity of Lp(a), and Lp(a) levels were measured in 220 patients with mild-to-moderate AS. The primary endpoint was the progression rate of AS, measured by the annualized increase in peak aortic jet velocity in m/s/year by Doppler echocardiography; the secondary endpoint was need for aortic valve replacement and cardiac death during 3.5 ± 1.2 years of follow-up.Results AS progression was faster in patients in the top tertiles of Lp(a) (peak aortic jet velocity: +0.26 ± 0.26 vs. +0.17 ± 0.21 m/s/year; p = 0.005) and OxPL-apoB (+0.26 ± 0.26 m/s/year vs. +0.17 ± 0.21 m/s/year; p = 0.01). After multivariable adjustment, elevated Lp(a) or OxPL-apoB levels remained independent predictors of faster AS progression. After adjustment for age, sex, and baseline AS severity, patients in the top tertile of Lp(a) or OxPL-apoB had increased risk of aortic valve replacement and cardiac death.Conclusions Elevated Lp(a) and OxPL-apoB levels are associated with faster AS progression and need for aortic valve replacement. These findings support the hypothesis that Lp(a) mediates AS progression through its associated OxPL and provide a rationale for randomized trials of Lp(a)-lowering and OxPL-apoB-lowering therapies in AS. (Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin [ASTRONOMER]; NCT00800800).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The clinical factors associated with faster stenosis progression include older age, female sex, severity of the stenosis and degree of aortic valve calcification at diagnosis, smoking, hypertension, obesity, metabolic syndrome, secondary hyperparathyroidism, renal failure elevated circulating levels of Lp(a), and increased activity of Lp-PLA2 (also called lipoprotein–associated phospholipase A2)51”
From Calcific aortic stenosis (2016) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In particular, the presence of elevated plasma Lp(a) (>50 mg per dL; the upper normal limit is <30 mg per dL)) is associated with a twofold faster stenosis progression51.”
From Calcific aortic stenosis (2016) · cites this paper as [51]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In addition, Capoulade and colleagues showed that circulating Lp(a) and Ox-PL levels were independently associated with faster progression of calcific AS51.”
From Calcific aortic stenosis (2016) · cites this paper as [51]
In the citing paper
“prior studies have linked ApoB to the onset and accelerated progression of CAVD [38,39].”
From Identifying novel drug targets for calcific aortic valve disease through Mendelian randomization (2025) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C., Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O’Gara, P. T., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.176857 · Cited by 8,487
Burden of valvular heart diseases: a population-based study
Nkomo, V. T., Gardin, J. M., Skelton, T. N., Gottdiener, J. S., Scott, C. G., & Enriquez-Sarano, M. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69208-8 · Cited by 4,881
Guidelines on the management of valvular heart disease
Vahanian, A. S., Baumgartner, H., Bax, J. J., Butchart, E., Dion, R., Filippatos, G. S., Flachskampf, F., Hall, R., Iung, B., Kasprzak, J. D., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehl428 · Cited by 3,579
Guidelines on the management of valvular heart disease (version 2012)
Authors/Task Force Members, Vahanian, A., Alfieri, O., Andreotti, F., Antunes, M. J., Barón-Esquivias, G., Baumgartner, H., Borger, M. A., Carrel, T. P., De Bonis, M., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs109 · Cited by 3,559
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
Nishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., Guyton, R. A., O’Gara, P. T., Ruiz, C. E., Skubas, N. J., Sorajja, P., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.536 · Cited by 3,523
Nishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., Guyton, R. A., O’Gara, P. T., Ruiz, C. E., Skubas, N. J., Sorajja, P., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000029 · Cited by 2,566
Stimulation of Bone Formation in Vitro and in Rodents by Statins
Mundy, G. R., Garrett, R., Harris, S., Chan, J., Chen, D., Rossini, G., Boyce, B. F., Zhao, M., & Gutierrez, G. (1999) · Science · doi:10.1126/science.286.5446.1946 · Cited by 1,776
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary
Nishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., Guyton, R. A., O'Gara, P. T., Ruiz, C. E., Skubas, N. J., Sorajja, P., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.537 · Cited by 1,642
Genetic Associations with Valvular Calcification and Aortic Stenosis
Thanassoulis, G., Campbell, C. Y., Owens, D. S., Smith, J. G., Smith, A. V., Peloso, G. M., Kerr, K. F., Pechlivanis, S., Budoff, M. J., Harris, T. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1109034 · Cited by 1,008
Flagged first, then by citations
Research works printed but not linked: 1
- Tsimikas, 2015, Antisense therapy targeting apolipoprotein (a) reduces plasma lipoprotein(a) Levels, Lancet
Cited by
Sorted by citations
Items 201–300 of 417
Lipoprotein(a) and aortic valve stenosis: work in progress
Kronenberg, F. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac436 · Cited by 13
Oxidized phospholipids are biomarkers, drug targets, and drug leads
Oskolkova, O., Birukova, A. A., Birukov, K. G., & Bochkov, V. N. (2022) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2022.1043708 · Cited by 14
Costanzo, A. D., Indolfi, C., Franzone, A., Esposito, G., & Spaccarotella, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914939 · Cited by 16
A Notch more: Molecular players in bicuspid aortic valve disease
Lee, A., Wei, S., & Schwertani, A. G. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.05.018 · Cited by 14
Drugs for Prevention and Treatment of Aortic Stenosis: How Close Are We?
Afshar, M. S., Yazdan-Ashoori, S., Engert, J. C., & Thanassoulis, G. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.02.017 · Cited by 14
Coassin, S., Chemello, K., Khantalin, I., Forer, L., Döttelmayer, P., Schönherr, S., Grüneis, R., Chong-Hong-Fong, C., Nativel, B., Ramin‐Mangata, S., et al. (2022) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.121.003489 · Cited by 13
Lipoprotein(a) in Cardiovascular Diseases: Insight From a Bibliometric Study
Šuran, D., Vošner, H. B., Završnik, J., Kokol, P., Sinkovič, A., Kanič, V., Kokol, M., Naji, F. H., & Završnik, T. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.923797 · Cited by 14
Mahabadi, A. A., Kahlert, P., Kahlert, H. A., Dykun, I., Balcer, B., Forsting, M., Heusch, G., & Rassaf, T. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.04.046 · Cited by 12
Lipoprotein(a) and aortic valve stenosis: A casual or causal association?
Santangelo, G., Faggiano, A., Bernardi, N., Carugo, S., Giammanco, A., & Faggiano, P. M. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.10.015 · Cited by 13
Lipoprotein(a) and calcific aortic valve disease: current evidence and future directions
Lan, N. S. R., Khan, Z. U., & Watts, G. F. (2023) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000976 · Cited by 11
Ghose, T. (2023) · Indian Heart Journal · doi:10.1016/j.ihj.2023.12.010 · Cited by 11
The Role of Lipoprotein(a) in Peripheral Artery Disease
Pavlatos, N., & Kalra, D. K. (2024) · Biomedicines · doi:10.3390/biomedicines12061229 · Cited by 14
Marrero, N., Jha, K. K., Razavi, A. C., Boakye, E., Anchouche, K., Dzaye, O. D. A., Budoff, M. J., Tsai, M. Y., Shah, S. J., Rotter, J. I., et al. (2024) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.123.016372 · Cited by 11
Nel, K., Nam, M. C. Y., Anstey, C., Boos, C. J., Carlton, E. W., Senior, R., Kaski, J. C., Khattab, A., Shamley, D. R., Byrne, C. D., et al. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.06.023 · Cited by 11
Nader, J., Metzinger, L., Maitrias, P., Caus, T., & Meuth, V. M. (2020) · Non-coding RNA Research · doi:10.1016/j.ncrna.2020.02.005 · Cited by 11
Wodaje, T., Littmann, K., Häbel, H., Bottai, M., Bäck, M., Parini, P., & Brinck, J. W. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.02.016 · Cited by 11
Lipoprotein(a): Insights for the Practicing Clinician
Telyuk, P., Austin, D., Luvai, A., & Zaman, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11133673 · Cited by 12
Tsamoulis, D., Siountri, I., & Rallidis, L. S. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10030096 · Cited by 11
Oxidized lipids: not just another brick in the wall
Stamenković, A., Pierce, G. N., & Ravandi, A. (2018) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2018-0490 · Cited by 11
Nicholls, S. J., & Bubb, K. J. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01528-w · Cited by 12
The Lipid Hypothesis in Calcific Aortic Valve Disease
Rajamannan, N. M., & Moura, L. M. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.307435 · Cited by 11
Identifying novel drug targets for calcific aortic valve disease through Mendelian randomization
Xu, D., Lu, J., Yang, Y., Hu, W., Chen, J., Xue, J., Yang, S., Cao, N., Hu, H., Qian, N., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119110 · Cited by 10
Effectiveness of cascade screening for elevated lipoprotein(a), an underdiagnosed family disorder
Annink, M. E., Janssen, E. S., & Reeskamp, L. F. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000951 · Cited by 10
Kaltoft, M., Afzal, S., Nordestgaard, B. G., Sigvardsen, P. E., Kühl, J. T., Fuchs, A., Køber, L., Kofoed, K. F., & Langsted, A. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf106 · Cited by 10
Anchouche, K., Baass, A. W., & Thanassoulis, G. (2025) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2025.110929 · Cited by 11
Zheng, Y., Li, Q., Yang, Y., Yang, J., Liu, Z., Ma, X., & Wang, Z. J. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.042112 · Cited by 12
The current landscape of lipoprotein(a) in calcific aortic valvular disease
Hsieh, G., Rizk, T., Berman, A. N., Biery, D. W., & Blankstein, R. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000901 · Cited by 10
Antiphospholipid antibodies in patients with calcific aortic valve stenosis
Plunde, O., Svenungsson, E., Ferrannini, G., Franco‐Cereceda, A., & Bäck, M. (2022) · Lara D. Veeken · doi:10.1093/rheumatology/keac466 · Cited by 10
Tsushima, T., Tsushima, Y., Sullivan, C., & Hatipoğlu, B. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.12.011 · Cited by 9
Hu, X., Wang, C., Feng, D., Li, Z., Chen, Y., Niu, G., Zhou, Z., Zhang, H., Ye, Y., Wang, M., et al. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.03.001 · Cited by 9
Girard, A. S., Paulin, A., Manikpurage, H. D., Lajeunesse, E., Clavel, M.-A. A., Pîbarot, P., Krege, J. H., Mathieu, P., Thériault, S., & Arsenault, B. J. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.038955 · Cited by 9
Self-citationSong, S., Lee, C. J., Oh, J., Park, S., Kang, S., & Lee, S. (2019) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2019.8.1.58 · Cited by 9
Fletcher, A. J., & Dweck, M. R. (2020) · Journal of Nuclear Cardiology · doi:10.1007/s12350-020-02411-x · Cited by 10
Xia, J., Guo, C., Cao, H., Liu, K., Peng, W., Sun, Y., Xie, Y., Li, B., Zhang, F., Wen, F., et al. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13689 · Cited by 9
Abdalla, H., Mahmoud, A., Khedr, A. E., Farina, J., Scalia, I. G., Abbas, M. T., Awad, K., Ali, N. B., Bismee, N. N., Esfahani, S. A., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011029 · Cited by 9
Statins—Their Effect on Lipoprotein(a) Levels
Granat, M. M. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm26162 · Cited by 9
Cinezan, C., Măgureanu, D. C., Hiceag, M. L., Rus, C. B., Ilias, I. T., Bogdan, I. D., Buzle, A. M., & Cozma, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178163 · Cited by 8
Oxyphospholipids in Cardiovascular Calcification
Chignon, A., Bon-Baret, V., Boulanger, M., Bossé, Y., & Mathieu, P. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.313790 · Cited by 8
Self-citationGirard, A. S., Gaillard, E., Puri, R., Capoulade, R., Chan, K. L., Paulin, A., Manikpurage, H. D., Dumesnil, J. G., Tam, J. W., Teo, K. K., et al. (2023) · European Heart Journal Open · doi:10.1093/ehjopen/oead032 · Cited by 8
Self-citationCapoulade, R., Chan, K. L., Mathieu, P., Bossé, Y., Dumesnil, J. G., Tam, J. W., Teo, K. K., Yang, X., Witztum, J. L., Arsenault, B. J., et al. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.03.013 · Cited by 8
Self-citationProgression of aortic stenosis in patients with bicuspid aortic valve
Shang, M., Kahler‐Quesada, A., Mori, M., Yousef, S., Geirsson, A., & Vallabhajosyula, P. (2021) · Journal of Cardiac Surgery · doi:10.1111/jocs.16026 · Cited by 8
The Haemodynamic and Pathophysiological Mechanisms of Calcific Aortic Valve Disease
Hanna, L., Armour, C. H., Xu, X. Y., & Gibbs, R. G. J. (2022) · Biomedicines · doi:10.3390/biomedicines10061317 · Cited by 10
Ruder, S., Mansfield, B. S., Immelman, A., Varki, N. M., Miu, P., Raal, F. J., & Tsimikas, S. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01720-z · Cited by 10
Self-citationAortic valve stenosis: the long and winding road
Kronenberg, F. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1069 · Cited by 9
Celeski, M., Nusca, A., Ciavaroli, N. G., Martucciello, A., Crisci, F., Polito, D., Mangiacapra, F., Cammalleri, V., Melfi, R., Gallo, P., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134709 · Cited by 7
Lipoprotein(a) in clinical practice: Risk stratification and therapeutic strategies
Nasrallah, N., Atallah, Harb, T., Gerstenblith, G., & Leucker, T. M. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70127 · Cited by 8
Fauvel, C., Coisne, A., Capoulade, R., Bourg, C., Diakov, C., Ribeyrolles, S., Jouan, J., Folliguet, T. A., Kibler, M., Dreyfus, J., et al. (2024) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2024.06.004 · Cited by 8
Self-citationAfanasieva, O. I., & Pokrovsky, S. N. (2019) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2019-5-101-108 · Cited by 7
Zhou, K., Guo, T., Xu, Y., & Guo, R. (2020) · Medical Science Monitor · doi:10.12659/msm.925260 · Cited by 7
Lp(a): a genetic cause of clinical FH in children
Averna, M. R., & Cefalu, A. B. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac789 · Cited by 7
Akinlonu, A. A., Boffa, M. B., Lyu, C., Zhong, J., Jindal, M., Fadzan, M., Garshick, M. S., Schwartzbard, A. Z., WEINTRAUB, H. S., Bredefeld, C., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.11.008 · Cited by 7
A collagen-based laboratory model to mimic sex-specific features of calcific aortic valve disease
Allgayer, R., Kabir, R., Bergeron, A., Demers, P., Mantovani, D., & Cerruti, M. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.01.034 · Cited by 5
The role of elevated lipoprotein(a) in aortic valve disease: a systematic review
Wambua, P., Wahinya, M., & Khan, Z. U. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1610395 · Cited by 6
Koschinsky, M. L., Kalra, D. K., & Boffa, M. B. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-050124-025051 · Cited by 6
Lipoprotein(a) and Its Role in Peripheral Arterial Disease: A Narrative Review
Mwipatayi, B. P., Dodd, J. E., Bazlee, A. H. A., Stratford, G., Lee, B., Mori, T. A., Watts, G. F., Armari, E., Wong, J., & Schlaich, M. P. (2025) · Vascular Health and Risk Management · doi:10.2147/vhrm.s555127 · Cited by 10
Analytical validation of monoclonal antibody-based ELISA methods for OxPL-apoB and OxPL-apo(a)
Marcovina, S. M., Smith, S., Kornel, J., Yang, X., & Tsimikas, S. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.100976 · Cited by 8
Self-citationAntibody E06 and the Role of Oxidized Phospholipids in Atherogenesis and Inflammation
Witztum, J. L., Que, X., Tang, W., & Tsimikas, S. (2026) · Circulation Research · doi:10.1161/circresaha.126.327359 · Cited by 6
Self-citationInterpretation of the central aortic pressure waveform in elderly patients with aortic stenosis
Hungerford, S. L., Adji, A. I., & Kapur, N. K. (2023) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00050.2023 · Cited by 6
Krzesińska, A., Nowak, M. M., Mickiewicz, A., Chyła-Danił, G., Ćwiklińska, A., Koper‐Lenkiewicz, O. M., Kamińska, J., Matowicka-Karna, J., Gruchała, M., Jankowski, M., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11071823 · Cited by 6
Efficacy of Traditional Anti-lipidemic Drugs in Lowering Lipoprotein(a) Levels: A Systematic Review
Sinha, M., Maged, R., Tarar, P., Bandi, V. V., Koneru, H. M., & Sarwar, H. (2024) · Cureus · doi:10.7759/cureus.69824 · Cited by 6
Novel Circulating Biomarkers in Aortic Valve Stenosis
Ong, J. Y.-S., Tan, S. M. L., Koh, A. S.-M., Kong, W. K. F., Sia, C., Yeo, T. C., Quek, S. C., & Poh, K. K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051902 · Cited by 6
Nayor, M. G., Shen, L., Hunninghake, G. M., Kochunov, P., Barr, R. G., Bluemke, D. A., Broeckel, U., Caravan, P. D., Cheng, S. C., de Vries, P. S., et al. (2021) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.121.012943 · Cited by 5
Liu, C., Liu, H., & Xie, T. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01625-x · Cited by 6
Is Lipoprotein(a) Clinically Actionable with Today’s Evidence? The Answer is Yes
Ma, G. S., Chiou, T. T., & Wilkinson, M. J. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01937-z · Cited by 5
Yuen, T., Mancini, G. B. J., Hegele, R. A., & Pearson, G. J. (2023) · CJC Open · doi:10.1016/j.cjco.2023.11.015 · Cited by 6
Notenboom, M. L., Hoof, L. V., Schuermans, A., Takkenberg, J. J. M., Rega, F., & Taverne, Y. J. H. J. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11020049 · Cited by 7
Motawea, K. R., Elhalag, R. H., Aboelenein, M. M., Ibrahim, N., Swed, S., Fathy, H., Awad, D. M., Belal, M. M., Talat, N. E., Rozan, S. S., et al. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101746 · Cited by 6
Tafciu, E., Mandoli, G. E., Santoro, C., Setti, M., D’Andrea, A., Esposito, R., Bandera, F., Evola, V., Malagoli, A., Cameli, M., et al. (2020) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001126 · Cited by 6
Current Management and Therapy of Severe Aortic Stenosis and Future Perspective
Takeji, Y., Tada, H., Taniguchi, T., Sakata, K., Kitai, T., Shirai, S., & Takamura, M. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22023 · Cited by 5
Patterson, A. J. S., Patil, V. A., Rios, L. F., Borelli, A. N., & Masters, K. S. B. (2024) · Journal of the Heart Valve Society · doi:10.1177/30494826241296675 · Cited by 6
Aortic Stenosis: Diagnosis, Molecular Mechanisms and Therapeutic Strategies—A Comprehensive Review
Banceu, C. M., Cristutiu, D., Gurzu, S., Harpa, M. M., Banceu, D. M., & Suciu, H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14144949 · Cited by 8
Lepodisiran: Effects on Lipoprotein(a) and Cardiovascular Outcomes in Adults with Elevated Lp(a)
Kattamuri, L. P. V., Sharma, K., & Mukherjee, D. (2025) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x390148250908045359 · Cited by 5
Determinants of Aortic Stenosis Progression in Bicuspid and Tricuspid Aortic Valves
Shen, M., Tastet, L. L., Capoulade, R., Bédard, É., Arsenault, M., Clavel, M.-A. A., & Pîbarot, P. (2022) · CJC Pediatric and Congenital Heart Disease · doi:10.1016/j.cjcpc.2022.06.004 · Cited by 5
Self-citationRole of follistatin-like 1 levels and functions in calcific aortic stenosis
Zhang, Q., Ye, J., Yang, G., Yang, L., Chen, Z., Yang, K., Sun, J. T., & Liu, Y. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1050310 · Cited by 5
Hober, A., Rekanovic, M., Forsström, B., Hansson, S., Kotol, D., Percy, A. J., Uhlén, M., Oscarsson, J., Edfors, F., & Miliotis, T. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281772 · Cited by 6
Atallah, Harb, T., Nasrallah, N., Jones, S. R., Gerstenblith, G., Tsimikas, S., & Leucker, T. M. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120469 · Cited by 5
Self-citationRole of Lipoprotein(a) in Cardiovascular Disease: A Review of Clinical Practice
Minami, Y., Kinoshita, D., Muramatsu, Y., Nagata, T., & Ako, J. (2022) · Journal of Asian Pacific Society of Cardiology · doi:10.15420/japsc.2021.31 · Cited by 5
Bonetti, A., Contin, M., Marchini, M., & Ortolani, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032667 · Cited by 5
Sherratt, S. C. R., Libby, P., Dunbar, R. L., Bhatt, D. L., & Mason, R. P. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf144 · Cited by 5
Insights into preclinical models of calcific aortic valve disease and their translational potential
Lafosse, I., Mentaverri, R., Avondo, C., Bennis, Y., Tribouilloy, C. M., & Hénaut, L. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1621990 · Cited by 6
Lipoprotein (a) Distribution in Aortic Stenosis Patients
Durr, M.-R. R., Burwash, I. G., LAU, L. S. W., Alfraidi, H., Mulloy, A. J., Tavoosi, A., Arangalage, D., Chan, V., Lakhani, M., Aljamaan, A., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101662 · Cited by 4
Brinck, J. W., Littmann, K., Hogling, D. E., Widman, L., Caidahl, K., Eriksson, M. J., Johnson, J., Szummer, K. E., & Bäck, M. (2025) · Journal of Internal Medicine · doi:10.1111/joim.20095 · Cited by 4
Burdeynaya, A. L., Afanasyeva, O. I., Александровна, К. Е., Tmoyan, N. A., Андреевна, Р. О., Afanasieva, M. I., Владиславович, Е. М., & Pokrovsky, S. N. (2021) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2021-2598 · Cited by 4
Aortic Valvular Stenosis and Heart Failure
Jean, G., Mogensen, N. S. B., & Clavel, M.-A. A. (2023) · Heart Failure Clinics · doi:10.1016/j.hfc.2023.02.005 · Cited by 4
Association between remnant cholesterol and progression of bioprosthetic valve degeneration
Li, Z., Zhang, B., Salaün, E., Côté, N., Mahjoub, H., Mathieu, P., Dahou, A., Zenses, A., Xu, Y., Pîbarot, P., et al. (2023) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jead159 · Cited by 4
Self-citationPoniedziałek, B., Perek, B., Proch, A., Komosa, A., Niedzielski, P., Buczkowski, P., Jemielity, M., & Rzymski, P. (2025) · Scientific Reports · doi:10.1038/s41598-025-85141-9 · Cited by 7
Valvular oxidized phospholipids correlate with severity of human aortic valvular stenosis
Resch, C. T., Stamenković, A., Surendran, A., Zhang, A., Oudit, G. Y., Shah, A. M., & Ravandi, A. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.07.042 · Cited by 4
Do Oxidized Lipoproteins Cause Atherosclerotic Cardiovascular Diseases?
Arsenault, B. J., Bourgeois, R., & Mathieu, P. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.09.016 · Cited by 4
Self-citationClinical Implications of Serum Biomarkers of Cardiac Stress in Aortic Stenosis
Patel, N. S., & Kumbhani, D. (2018) · Current Heart Failure Reports · doi:10.1007/s11897-018-0403-y · Cited by 5
Preventing Aortic Stenosis by Changing the Way We Think About an Old Disease
Thanassoulis, G. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.0722 · Cited by 4
Lp(a) and Accelerated Progression of Aortic Stenosis
Tsimikas, S. (2024) · JACC Asia · doi:10.1016/j.jacasi.2024.08.008 · Cited by 4
Self-citationSerum metabolic profiling in rheumatic heart disease and degenerative aortic stenosis
Mutithu, D. W., Kirwan, J., Adeola, H. A., Aremu, O. O., Lumngwena, E. N., Familusi, M. A., Wiesner, L., Skatulla, S., Naidoo, R., & Ntusi, N. (2025) · Scientific Reports · doi:10.1038/s41598-025-03149-7 · Cited by 3
Lipoprotein(a) Lowering with Pelacarsen (TQJ230)
Sharma, K., Kattamuri, L. P. V., & Mukherjee, D. (2025) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x399029250923100015 · Cited by 4
Loewenstein, I., Lichtenstein, D., Goldiner, I., Ben‐Shoshan, J., Halkin, A., Konigstein, M., Banai, S., Arbel, Y., Finkelstein, A., & Steinvil, A. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101264 · Cited by 3
Recent clinical trials in valvular heart disease
Kiss, D., & Anwaruddin, S. (2017) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000414 · Cited by 3
Mellwig, K. P., & Vogt, A. (2019) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-019-00100-9 · Cited by 3
Stöbe, S., Kandels, J., Metze, M., Tayal, B., Laufs, U., & Hagendorff, A. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1101493 · Cited by 3
Šuran, D., Završnik, T., Kokol, P., Kokol, M., Sinkovič, A., Naji, F. H., Završnik, J., Vošner, H. B., & Kanič, V. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12093220 · Cited by 3
Moderate Aortic Stenosis—Advanced Imaging, Risk Assessment, and Treatment Strategies
Adrichem, R., van den Dorpel, M. M. P., Hirsch, A., Geleijnse, M. L., Budde, R. P. J., & Mieghem, N. M. V. (2024) · Structural Heart · doi:10.1016/j.shj.2023.100279 · Cited by 3
Biologically Active Lipids in Vascular Biology
Upchurch, C. M., & Leitinger, N. (2019) · Learning materials in biosciences · doi:10.1007/978-3-030-12270-6_9 · Cited by 3
Metadata
- Authors
- Capoulade, R., Chan, K. L., Yeang, C., Mathieu, P., Bossé, Y., Dumesnil, J. G., Tam, J. W., Teo, K. K., Mahmut, A., Yang, X., Witztum, J. L., Arsenault, B. J., Després, J.-P., Pibarot, P., & Tsimikas, S.
- Affiliations
- Institut universitaire de cardiologie et de pneumologie de Québec (CA)
- Ottawa Heart Institute (CA)
- University of California San Diego (US)
- St. Boniface Hospital (CA)
- McMaster University (CA)
- Corresponding author
- Tsimikas, Sotirios
- ORCID
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2015-09
- Volume
- 66
- Issue
- 11
- Pages
- 1236-1246
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W1609565130
- Cited by
- 417
- References
- 45
- Citations by year
- 2026: 26 · 2025: 49 · 2024: 37 · 2023: 37 · 2022: 52 · 2021: 30 · 2020: 40 · 2019: 47 · 2018: 26 · 2017: 38 · 2016: 32 · 2015: 3
- FWCI
- 24.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Corpus Université Laval (Université Laval) (submittedVersion)
- Funders
- Abbott Laboratories
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- National Institutes of Health (HL055798, HL088093)
- University of California, San Diego
- Pfizer Canada
- Eli Lilly Canada
- Canadian Institutes of Health Research (MOP# 114997, MOP-245048, 114997, 245048)
- National Heart, Lung, and Blood Institute (HL-055798, HL093767, R01HL093767, HL119828, P01HL055798, R01HL119828, HL-088093, P01HL088093)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- aortic stenosis, calcific aortic stenosis, lipoprotein(a), oxidized phospholipids, apolipoprotein B-100, disease progression, aortic jet velocity, aortic valve replacement, cardiovascular mortality, valve calcification, Lp(a)-lowering therapy
- MeSH terms
- Adult, Aged, Aortic Valve, Aortic Valve Stenosis, Calcinosis, Death, Female, Humans, Male, Middle Aged, Oxidation-Reduction, Phospholipids, Ultrasonography, Biomarkers, Lipoprotein(a), Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
